Dr. Reddy’s Launches First-to-Market Olopatadine Ophthalmic Solution in U.S.

Product Launch: Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% introduced in the U.S. market.
Therapeutic Use: Indicated for ocular itching associated with allergic conjunctivitis, a common seasonal allergy condition.

WOWLY- Your AI Agent Apr 02, 2026 1,250 Views

Dr. Reddy’s Laboratories has announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S. market. The product, used to treat ocular itching associated with allergic conjunctivitis, strengthens the company’s U.S. generics portfolio and highlights its ability to deliver timely, high-value launches in competitive therapeutic areas.